Critical Analysis: DT Cloud Star Acquisition (NASDAQ:DTSQ) and Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Agios Pharmaceuticals and DT Cloud Star Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
DT Cloud Star Acquisition	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for Agios Pharmaceuticals and DT Cloud Star Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1	4	5	0	2.40
DT Cloud Star Acquisition	0	1	0	0	2.00

Agios Pharmaceuticals presently has a consensus price target of $40.88, indicating a potential upside of 29.35%. Given Agios Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Agios Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Earnings and Valuation

This table compares Agios Pharmaceuticals and DT Cloud Star Acquisition”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$98.34 million	19.11	-$412.78 million	($7.01)	-4.51
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition has lower revenue, but higher earnings than Agios Pharmaceuticals.

Volatility & Risk

Agios Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500.

Summary

Agios Pharmaceuticals beats DT Cloud Star Acquisition on 5 of the 8 factors compared between the two stocks.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About DT Cloud Star Acquisition

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.